Effects of the Angiotensin II Receptor Antagonist Candesartan Cilexetil on Blood Pressure and Proteinuria in Patients with Autosomal Dominant Polycystic Kidney Disease

Nephron ◽  
2000 ◽  
Vol 86 (3) ◽  
pp. 385-386 ◽  
Author(s):  
Tsukasa Nakamura ◽  
Chifuyu Ushiyama ◽  
Noriaki Shimada ◽  
Keiko Sekizuka ◽  
Isao Ebihara ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Angiotensin Ii ◽  
Kidney Disease ◽  
Receptor Antagonist ◽  
Autosomal Dominant ◽  
Candesartan Cilexetil ◽  
Angiotensin Ii Receptor ◽  
Polycystic Kidney ◽  
Angiotensin Ii Receptor Antagonist ◽  
Autosomal Dominant Polycystic Kidney

Autosomal dominant polycystic kidney disease management

2018 ◽  
Author(s):  
Young-Hwan Hwang ◽  
York Pei
Keyword(s):  
Blood Pressure ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Kidney Volume ◽  
Polycystic Kidney ◽  
Renal Disease Progression ◽  
Kidney Size ◽  
Autosomal Dominant Polycystic Kidney ◽  
Cyst Growth

Management of patients with autosomal dominant polycystic kidney disease (ADPKD) currently comprises non-specific measures including promotion of healthy lifestyle, optimization of blood pressure control, and modification of cardiovascular risk factors. A high water intake of 3–4 L per day in patients with glomerular filtration rate greater than 30 mL/min/1.73 m2 may decrease the risk of kidney stones, but its potential benefit in reducing renal cyst growth is presently unproven. Maintenance of a target blood pressure of 130/80 mmHg is recommended by expert clinical guidelines though this is unlikely to slow cyst growth. It is unclear whether pharmacological blockade of the renin–angiotensin axis confers an extrarenal protective effect. Recognition of the variable clinical presentations of cyst infection, cyst haemorrhage, or nephrolithiasis is important for early diagnosis and optimal management of these complications. Most patients with ADPKD do well on dialysis and after transplantation. Nephrectomy may be needed to make space for a donor kidney, or if kidney size or infection is an issue after end-stage renal failure is reached. Recent advances in ADPKD have led to the identification of multiple potential therapeutic targets with more than 10 clinical trials completed or currently in progress. Given the promising results of the TEMPO trial, tolvaptan may well be the first disease-modifying drug to be approved for clinical use. Several other classes of drugs (e.g. somatostatin analogues, triptolide, metformin, and glucosylceramide synthase inhibitors) with good long-term safety profiles are promising candidates which may be repurposed for this disease. In the future, identifying patients with different risks of renal disease progression by their genotype and/or kidney volume will likely assume an important role for the clinical management of ADPKD.

Sign in / Sign up

Export Citation Format

Share Document